US6020212A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Phycobiliprotein-linker peptide complex fluorescent tracer and methods of using the same
Assignee: CIS Bio International SA
•
Filing: 1996-06-07
•
Granted: 2000-02-01
•
Expires: 2016-06-07
Abstract
Abstract PCT No. PCT/FR96/00865 Sec. 371 Date Feb. 23, 1998 Sec. 102(e) Date Feb. 23, 1998 PCT Filed Jun. 7, 1996 PCT Pub. No. WO96/42016 PCT Pub. Date Dec. 27, 1996The use of a phycobiliprotein-linker peptide complex as a fluorescent tracer in a fluorescent method of detecting and/or determining an analyte in a medium in which it may be present, is disclosed. Fluorescent conjugates consisting of said complex covalently bonded to one of the elements of a ligand/receptor specific binding pair, are also disclosed.
Inventors
- 👤 Gerard Mathis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 10:06
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/532; G01N33/533; C; C07; C07K; C07K14/00; C07K14/195; Y; Y10; Y10S; Y10S436/00; Y10S436/80; Y10S436/811; Y10S436/813
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
31 words
A fluorescent method of detecting and/or determining an analyte in a medium in which it may be present, characterised in that a phycobiliprotcin-linker peptide complex is used as a fluorescent tracer.
Claim 2
Dependent Claim
31 words
A fluorescent method of detecting and/or determining an analyte in a medium in which it may be present, characterised in that a phycobiliprotcin-linker peptide complex is used as a fluorescent tracer.
Claim 3
Dependent Claim
26 words
The method according to claim 1, characterised in that the phycobiliprotein of said phycobiliprotein-linker peptide complex is selected from phycocrythrin, phycoerythrocyanine, phycocyanine, allophycocyanine and allophycccyanine B.
Claim 4
Dependent Claim
31 words
The method according to claim 1 characterised in that the phycobiliprotein-linker peptide complex is extracted from a cyanobacterium selected from Mastigoclodus Laminosus, Synechocystis 6701, Synechococcus, 6301, Anabaena variabilis and Nostoc spec.
Claim 5
Dependent Claim
34 words
The method according to claim 1, characterised in that the linker peptide of said phycobiliprotein-linker peptide complex is selected from the peptides L R , L C , L RC and L CM .
Claim 6
Dependent Claim
101 words
The method according to claim 1, characterised in that the phycobiliprotein-linker peptide complex is selected from the complexes (α PEC , β PEC ) 6 L R , (α PEC , β PEC ) 3 L R , (α PC , β PC ) 6 L R , (α PC , β PC ) 6 L RC , (α PC , β PC ) 3 L R , (α AP , β AP ) 3 L C , (α APB , [α2]α 2 AP , [B3]β 3 AP )L C and (α AP , β AP ) 2 L CM .
Claim 7
Dependent Claim
184 words
A homogenous fluorescent method of detecting and/or determining an analyte in a medium in which it may be present, by displaying the product of the reaction between the analyte and at least one corresponding receptor, consisting of: 1) adding to said medium a first reagent constituted of at least one receptor of said analyte, 2) adding a second reagent selected from the analyte or at least one of its receptors, one of said first reagent or said second reagent coupled with a flourescent donor compound constituted by a rare earth cryptate, chelate or macrocyclic complex and other reagent being coupled with a fluorescent acceptor compound, it being possible for the order of addition of the reagents to be the reverse order and, after excitation of the mixture by a source of light at the excitation wavelength of the fluorescent donor compound, 3) measuring the emission signal of the fluorescent acceptor compould, and 4) correlating the measured emission signal of the fluorescent acceptor compound to the presence and/or amount of analyte, characterised in that a phycobiliprotein-linker peptide complex is used as a fluorescent acceptor compound.
Claim 8
Dependent Claim
184 words
A homogenous fluorescent method of detecting and/or determining an analyte in a medium in which it may be present, by displaying the product of the reaction between the analyte and at least one corresponding receptor, consisting of: 1) adding to said medium a first reagent constituted of at least one receptor of said analyte, 2) adding a second reagent selected from the analyte or at least one of its receptors, one of said first reagent or said second reagent coupled with a flourescent donor compound constituted by a rare earth cryptate, chelate or macrocyclic complex and other reagent being coupled with a fluorescent acceptor compound, it being possible for the order of addition of the reagents to be the reverse order and, after excitation of the mixture by a source of light at the excitation wavelength of the fluorescent donor compound, 3) measuring the emission signal of the fluorescent acceptor compould, and 4) correlating the measured emission signal of the fluorescent acceptor compound to the presence and/or amount of analyte, characterised in that a phycobiliprotein-linker peptide complex is used as a fluorescent acceptor compound.
Claim 9
Dependent Claim
128 words
The method according to claim 6 which consists of an excess method, characterised in that it consists of: 1) adding to said medium containing the analyte sought after a first reagent constituted by at least one receptor of said analyte coupled with a fluorescent donor compound constituted by a rare earth cryptate, chelate or macrocyclic complex, 2) adding a second reagerit constituted by one or more other receptors of said analyte, said second reagent being coupled with a fluorescent acceptor compound constituted by a phycobiliprotein-linker peptide complex, 3) incubating said medium after each addition of reagents or after the addition of the second reagent, 4) exciting the resulting medium at the excitation wavelength of the fluorescent donor compound, 5) measuring the signal emitted by the fluorescent acceptor compound.
Claim 10
Dependent Claim
115 words
The method according to claim 6 consisting of a competitive method, characterised in that it consists of: 1) adding to said medium containing the analyte sought after a first reagent constituted by a receptor of said analyte, coupled with a fluorescent donor compound constituted by a rare earth cryptate, chelate or macrocyclic complex, 2) adding a second reagent constituted of the analyte coupled with a fluorescent acceptor compound constituted by a phycobiliprotein-linker peptide complex, 3) incubating said medium after each addition of reagents or after the addition of the second reagent, 4) exciting the resulting medium at the excitation wavelength of the fluorescent donor compound, 5) measuring the signal emitted by the fluorescent acceptor compound.
Claim 11
Dependent Claim
118 words
The method according to claim 6 consisting of a competitive method, characterised in that it consists of: 1) adding to said medium containing the analyte sought after a first reagent constituted by a receptor of said analyte, said receptor being coupled with a fluorescent acceptor compound constituted by a phycobiliprotein-linker peptide complex, 2) adding a second reagent constituted of the analyte coupled with a fluorescent donor compound constituted by a rare earth cryptate or chelate, 3) incubating said medium either after the addition of each reagent, or after the addition of the second reagent, 4) exciting the resulting medium at the excitation wavelength of he fluorescent donor compound, 5) measuring the signal emitted by the fluorescent acceptor compound.
Claim 12
Independent Claim
32 words
The method according to any one of claims 6 to 9, characterised in that the first reagent and the second reagent are added simultaneously to the medium containing the analyte sought after.
Claim 13
Independent Claim
37 words
The method according to any one of claims 6 or 7, characterised in that one sole receptor of the analyte is used which is coupled either with the fluorescent donor compound, or with the fluorescent acceptor compound.
Claim 14
Independent Claim
28 words
The method according to any one of claims 6 to 9, characterised in that the fluorescent donor compound is a terbium or europium chelate, cryptate or macrocyclic complex.
Claim 15
Independent Claim
44 words
The method according to any one of claims 6 to 9 characterised in that the fluorescent donor compound is an Eu 3+ chelate, cryptate or macrocyclic complex and the fluorescent acceptor compound is the (α AP , β AP ) 3 L C complex.
Claim 16
Dependent Claim
85 words
A method of amplification of the emission signal of a rare earth cryptate or chelate used as fluorescent donor compound in a fluorescent assay according to claim 1, in which a fluorescent acceptor compound is also used, characterised in that the rare earth clyptate or chelate possesses a low overall quantum yield, and in that the quantum yield of radiative deactivation from the emission level of the rare earth is lower than the quantum yield of the acceptor being constituted by a phycobiliprotein-linker peptide complex.
Claim 17
Dependent Claim
24 words
The method according to claim 1, characterised in that the phycobiliprotein-linker peptide complex is used in combination with one or more different fluorescent tracers.
Claim 18
Dependent Claim
22 words
A fluorescent conjugate constituted of a phycobiliprotein-linker peptide complex covalently bound to one of the elements of a ligand/receptor specific binding pair.
Claim 19
Dependent Claim
22 words
A fluorescent conjugate constituted of a phycobiliprotein-linker peptide complex covalently bound to one of the elements of a ligand/receptor specific binding pair.
Claim 20
Dependent Claim
26 words
The conjugate according to claim 16, characterized in that the phycobiliprotein of said phycobiliprotein-linker peptide complex is selected from phycoerythrin, phycoerythrocyanine, phycocyanine, allophycocyanine and allophycocyanine B.
Claim 21
Dependent Claim
36 words
The conjugate according to claim 16 or 17, characterized in that the linker peptide of said phycobiliprotcin-linkcr peptide complex is selected from the peptides L R , L C , L RC and L CM .
Claim 22
Dependent Claim
105 words
The conjugate according to one of claims 16 or 17, characterised in that the phycobiliprotein-linker peptide complex is selected from the complexes (α PEC , β PEC ) 6 L R , (α PEC , β PEC ) 3 L R , (α PC , β Pc ) 6 L R , (α PC , β PC ) 6 L RC , (α PC , β PC ) 3 L R , (α AP , β AP ) 3 L C , (α APB , [α2]α 2 AP ; [B3]β 3 AP )L C and (α AP , β AP ) 2 L CM .
Claim 23
Dependent Claim
35 words
The conjugate according to one of claims 16 or 17, characterised in that the phycobiliprotein-linker peptide complex is extracted from a c),anobacterium selectcd from Mastigoclodus Laminosus, Synechocystis 6701, Synechococcis 6301, Anabaena variabilis and Nostoc spec.
Claim 24
Dependent Claim
20 words
The conjugate according to claim 16, characterised in that the element of the ligand/receptor specific binding pair is a receptor.
Claim 25
Dependent Claim
20 words
The conjugate according to claim 16, characterised in that the element of the ligand/receptor specific binding pair is a ligand.
Claim 26
Dependent Claim
16 words
A flow cytometry method characterized by the use of the conjugate of claim 16 or 17.
Claim 27
Dependent Claim
22 words
The method of claim 6 wherein phycobiliprotein of said phycobiliprotein-linker peptide complex is selected from phycoerythrin, phycoerythrocyanine, phycocyanine, allophycocyanine and allophycocyanine B.
Claim 28
Dependent Claim
28 words
The method of claim 6 wherein said phycobiliprotein-linker peptide complex is extracted from a cyanobacterium selected from Mastigoclodus Laminosus, Synechocystis 6701, Synechococcus, 6301, Anabaena variabilis and Nostoc spec.
Claim 29
Dependent Claim
31 words
The method of claim 6 wherein the linker peptide of said phycobiliprotein-linker peptide complex is selected from the peptides L R , L C , L RC and L CM .
Claim 30
Dependent Claim
96 words
The method of claim 6 wherein said phycobiliprotein-linker peptide complex is selected from the complexes (α PEC , β PEC ) 6 L R , (α PEC , β PEC ) 3 L R , (α PC , β PC ) 6 L R , (α PC , β PC ) 6 L RC , (α PC , β PC ) 3 L R , (α AP , β AP ) 3 L C , (α APB , α2 AP , B3 AP )L C and (α AP , β AP ) 2 L CM .
Claim 31
Dependent Claim
15 words
The conjugate of claim 21 wherein said receptor is a cell receptor or an antibody.
Claim 32
Dependent Claim
11 words
The conjugate of claim 22 wherein said ligand is an analyte.
References Cited (Backward Citations)
EP0076695A1
Cited
US4520110A
Cited
US4542104A
Cited
EP0174744A2
Cited
US4857474A
Cited
US5512493A
Cited
US5457184A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-01-31 | 2003-08-02 | 2004-02-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-01-31 | 2007-08-02 | 2008-02-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-01-31 | 2011-08-02 | 2012-02-01 | $7700.00 | Window Closed / Lapsed |